Actively Recruiting
Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction
Led by Stanford University · Updated on 2024-11-25
70
Participants Needed
1
Research Sites
377 weeks
Total Duration
On this page
Sponsors
S
Stanford University
Lead Sponsor
N
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of a drug to prevent VIDD.
CONDITIONS
Official Title
Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients undergoing esophagectomy
You will not qualify if you...
- Patients with more than mild pulmonary dysfunction
- Patients with any neuromuscular disease that might compromise diaphragm function
- Patients with abnormal liver or kidney function
- Patients taking any immunosuppressant medication (including prednisone) or antifungal medications
- History of tuberculosis
- Weight loss of >5% of body weight over previous 6 months
- Pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Stanford University Medical Center
Stanford, California, United States, 94305
Actively Recruiting
Research Team
C
Cheyenne A Clinical Research Coordinator, B.S, M.S
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here